CATHEPSIN ASSESSMENT AND ITS CORRELATION WITH PARATHYROID HORMONE, ESTROGEN AND VITAMIN D LEVEL IN OSTEOPOROSIS PATIENTS

Abstract

The study was conducted from September 20, 2022, to May 1, 2023. The study sought to assess the function of cathepsin and its correlation with various physiological and biochemical factors in women. A total of 90 samples were obtained from two hospitals, Medical City and Al-SADER Teaching Hospital, located in Hilla Governorate. The study was partitioned into four distinct groups, the first group consisted of 22 pregnant females, the second group consisted of 22 females experiencing menopause, the third group consisted of 22 females with osteoporosis (OP) and the fourth group consisted of 24 seemingly healthy females. This is accomplished by measuring the physiological, enzymatic, hormonal and biochemical factors present in the blood serum. These factors include the enzyme cathepsin, estrogen, parathyroid hormone (PTH), vitamin D. The study results indicated a notable rise in the cathepsin concentration, PTH among the study groups compared to the control group. Additionally, there was a significant decrease in vitamin D concentration in the study groups compared to the control group. Furthermore, the pregnant women exhibited a substantial increase in estrogen hormone levels. In contrast, women with osteoporosis in menopause showed a significant decrease in estrogen hormone levels compared to the control group. This finding suggests a strong association between fragility disease and various groups of women, including pregnant women, women in menopause and those affected by osteoporosis.